Read the two contracts against each other and the pricing logic falls out. The Phase 1 obesity molecule drew 2.53 times the upfront cash of the Phase 2 candidate [1] and a headline ceiling 1.83 times as large [2], so what moved the price was indication rather than trial maturity: muscle-sparing weight loss on one side [3], short bowel syndrome on the other [5]. The seller and the research budget were identical in both.
(A caution on the won figures, since those are what the filings lead with: 1.8973 trillion won for $1.26 billion implies 1,506 won to the dollar [3], while 262.9 billion for $190 million implies 1,384 [4], roughly 9% apart [5], which makes the combined 5.0865 trillion won a sum taken at two different exchange rates.)
Earnings quality is where I would push back. Second-quarter operating profit rose 116.9% to 131.1 billion won with the Lilly agreement credited as a help [6], which puts the year-ago quarter near 60.4 billion [6], and the Lilly upfront by itself was 112.9 billion [5]. The disclosure as reported does not say how much of that landed inside the quarter, so treat the extreme case as a bound rather than a finding: full recognition in Q2 would leave about 18.2 billion won of everything else [7], near 30% of the prior-year quarter [8].
The research case is stronger, and it is cumulative rather than annual. Spending of 205.0, 209.8 and 229.0 billion won across the three years to last year totals 643.8 billion [9], against which 375.8 billion of upfronts returns 58% in cash carrying no obligation to repeat [10]. At 14 to 15% of revenue, that 229.0 billion implies annual sales between 1.53 and 1.64 trillion won [13], which makes three months of signing money worth 23 to 25% of a year's turnover [14].
Analysts quoted by Seoul Economic Daily read the two deals as the payoff from steady research spending [10]. This is probably wrong, but I would put it narrower: the ratio buys the ticket and the buyer sets the price, and Hanmi's own arithmetic argues it better than I can, because the discipline was the same across both programs and the obesity asset still cleared 2.5 times the cash a phase earlier [1]. The thesis fails in two visible ways. If HM17321 disappoints in Phase 1 [3] and no milestone triggers, the 5.09 trillion won ceiling [1] resolves to 262.9 billion won received [4] and an asset back on the shelf; and if a Korean mid-cap with a comparable research ratio lands an upfront of this size on a non-obesity Phase 1 candidate, then the spending rather than the indication was doing the pricing, and I would take the correction.
